Christina Herder, Idogen acting CEO
May 30, 2023 07:18 AM EDTUpdated 08:43 AM
R&D
Cell/Gene Tx

With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

Katherine Lewin

News Reporter

Small cell ther­a­py com­pa­ny Ido­gen will have to liq­ui­date the com­pa­ny if an­oth­er so­lu­tion isn’t found soon, like a re­verse merg­er or the sale of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times